Incyte CORP (INCY) — SEC Filings

Overview

Incyte CORP (INCY) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 26, 2026: Incyte Corp. filed an 8-K on March 26, 2026, reporting changes in officer titles, specifically under Item 5.02. While the filing indicates a 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,' the accomp

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 3 bullish, 30 neutral. The dominant filing sentiment for Incyte CORP is neutral.

Filing Type Overview

Incyte CORP (INCY) has filed 10 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 4 SC 13G/A, 3 SC 13D/A, 1 DEFA14A, 1 10-K/A with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

• Incyte Corp. Reports Officer Title Changes in 8-K Filing — 8-K · Mar 26, 2026
  Incyte Corp. filed an 8-K on March 26, 2026, reporting changes in officer titles, specifically under Item 5.02. While the filing indicates a 'Departure of Direc
• Incyte Corp Reports Director/Officer Changes & Compensation — 8-K · Dec 12, 2025 Risk: medium
  Incyte Corporation filed an 8-K on December 12, 2025, reporting events as of December 10, 2025. The filing pertains to the departure of directors or certain off
• Incyte's Q3 Net Income Soars on Strong Product Sales, R&D Cuts — 10-Q · Oct 28, 2025 Risk: low
  Incyte Corporation reported a significant increase in net income for the nine months ended September 30, 2025, reaching $987.371 million, a substantial turnarou
• Incyte Corp (INCY) Reports Executive & Director Changes — 8-K · Oct 3, 2025 Risk: low
  On September 30, 2025, Incyte Corporation (INCY) filed an 8-K report detailing changes in its executive and director positions. The filing indicates a departure
• Incyte Corp Reports Officer and Director Changes — 8-K · Aug 7, 2025 Risk: low
  Incyte Corporation filed an 8-K on August 7, 2025, reporting changes effective August 4, 2025. The filing pertains to the departure of directors or certain offi
• Incyte's Q2 Revenue Jumps 13.3% on Strong Product Sales — 10-Q · Jul 29, 2025 Risk: medium
  Incyte Corp reported a significant increase in product revenue for the second quarter of 2025, reaching $775.0 million, up from $700.0 million in the second qua
• Incyte Corp (INCY) Files 8-K: Director Changes & Executive Compensation — 8-K · Jun 27, 2025 Risk: low
  On June 23, 2025, Incyte Corporation (INCY) filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Incyte Corp Files 8-K: Board, Compensation, and Shareholder Votes — 8-K · Jun 11, 2025 Risk: low
  On June 10, 2025, Incyte Corporation filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also in
• Incyte Corp (INCY) Files 8-K: Other Event — 8-K · May 14, 2025 Risk: medium
  On May 11, 2025, Incyte Corporation (INCY) filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself,
• Incyte Corp Files 2025 Proxy Statement — DEF 14A · Apr 29, 2025 Risk: low
  Incyte Corporation filed its definitive proxy statement (DEF 14A) on April 29, 2025, for its annual meeting on June 10, 2025. The filing details the company's g
• Incyte Corp Q1 2025 10-Q Filed — 10-Q · Apr 29, 2025 Risk: medium
  Incyte Corporation filed its 10-Q for the period ending March 31, 2025. The filing details financial performance for the first quarter of 2025, including revenu
• Incyte Corp Files 2024 10-K — 10-K · Feb 10, 2025 Risk: medium
  Incyte Corporation filed its 2024 10-K on February 10, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Wilmington, De
• Incyte Corp Appoints New CMO, Director; CMO Departs — 8-K · Jan 10, 2025 Risk: low
  On January 6, 2025, Incyte Corporation (INCY) reported changes in its executive and director roles. The company announced the election of Dr. Paul J. Gaydos as
• SC 13G Filing — SC 13G · Nov 8, 2024
• Incyte Corp Q3 2024 10-Q Filing — 10-Q · Oct 29, 2024 Risk: medium
  Incyte Corporation filed its 10-Q for the period ending September 30, 2024. The company reported revenue from product sales and royalties, with specific figures
• SC 13G Filing — SC 13G · Oct 21, 2024
• SC 13G Filing — SC 13G · Oct 17, 2024
• Incyte Corp Q2 2024 10-Q Filing — 10-Q · Jul 30, 2024 Risk: medium
  Incyte Corporation filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the y
• SC 13G/A Filing — SC 13G/A · Jul 24, 2024
• Incyte Corp Enters Material Definitive Agreement — 8-K · Jul 3, 2024 Risk: medium
  On June 28, 2024, Incyte Corporation entered into a Material Definitive Agreement related to a direct financial obligation. The filing indicates the creation of
• Baker Bros. Advisors Amends Incyte Corp. Stake Filing — SC 13D/A · Jun 14, 2024 Risk: medium
  Baker Bros. Advisors LP, along with its group members, filed an amendment to their Schedule 13D on June 14, 2024, regarding their beneficial ownership of Incyte
• Incyte Corp Files 8-K on Shareholder Votes and Financials — 8-K · Jun 14, 2024 Risk: low
  Incyte Corporation filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 12, 2024. The
• Incyte Corp Files Proxy Statement — DEFA14A · May 30, 2024 Risk: low
  Incyte Corporation filed a Definitive Proxy Statement (DEFA14A) on May 30, 2024, detailing matters to be voted on by shareholders. The filing outlines the compa
• Baker Bros. Advisors amends Incyte Corp. 13D filing — SC 13D/A · May 13, 2024 Risk: medium
  Baker Bros. Advisors LP, along with associated entities and individuals, has filed an amendment to their Schedule 13D, indicating a change in their beneficial o
• Baker Bros. Advisors Updates Incyte Corp. Stake — SC 13D/A · May 9, 2024 Risk: medium
  Baker Bros. Advisors LP, along with its affiliates, has filed an amendment to their Schedule 13D, indicating a change in their beneficial ownership of Incyte Co
• Incyte Corp. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 30, 2024 Risk: medium
  INCYTE CORP (INCY) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Incyte Corp. reported financial results for the quarter ended March 31, 2024.
• Incyte Corp. Files Definitive Proxy Statement for 2024 Annual Meeting — DEF 14A · Apr 29, 2024 Risk: low
  INCYTE CORP (INCY) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Incyte reported 14% product and royalty revenue growth in 2023, reaching $3
• SC 13G Filing — SC 13G · Mar 25, 2024
• Incyte Corp Files Amendment to Annual Report — 10-K/A · Feb 16, 2024 Risk: low
  INCYTE CORP (INCY) filed a Amended Annual Report (10-K/A) with the SEC on February 16, 2024. Incyte Corporation filed an amendment (10-K/A) to its annual report
• Vanguard Amends Incyte Stake to 14.7% as of Dec 29, 2023 — SC 13G/A · Feb 13, 2024 Risk: low
  The Vanguard Group, a major investment firm, filed an amended Schedule 13G/A on February 13, 2024, updating its ownership in Incyte Corp. As of December 29, 202
• Dodge & Cox Amends Incyte Corp. (INCY) Stake — SC 13G/A · Feb 13, 2024 Risk: low
  Dodge & Cox, a California-based investment firm, filed an amended Schedule 13G/A on February 13, 2024, indicating their ownership of Incyte Corporation's common
• Incyte Corp Files 2023 Annual Report on Form 10-K — 10-K · Feb 13, 2024 Risk:
  INCYTE CORP (INCY) filed a Annual Report (10-K) with the SEC on February 13, 2024. Incyte Corp filed its 10-K report for the fiscal year ending December 31, 202
• BlackRock Updates Incyte Stake: SC 13G/A Amendment 10 Filed — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, indicating its ownership of Incyte Corporation's common stock as of December 31, 2023. This amendm

Related Companies

PFE · BMY

Frequently Asked Questions